Cannabis has taken center stage in modern pharmacotherapy, particularly as an antiemetic agent. For decades, cannabinoids have demonstrated their ability to inhibit the nausea and vomiting associated with aggressive oncological treatments by acting on the vomiting center in the medulla oblongata. However, pharmacology is rarely linear. In a paradoxical twist that has recently captured the attention of the medical community, the chronic and frequent use of this plant has given rise to a distinct clinical entity: cannabinoid hyperemesis syndrome (CHS). This phenomenon represents one of the most illustrative examples of how the interaction between a natural drug and human physiology can generate opposite effects depending on the pattern of use.
In brief
- Clinical duality: Cannabis treats chemotherapy-induced vomiting, but chronic use can cause it.
- Pathognomonic criterion: Symptomatic relief after hot baths or showers is the key diagnostic indicator.
- Hypothetical mechanism: Desensitization of CB1 receptors in the digestive tract and their reactivation by heat.
- Real but rare risk: Estimated at 1% to 7% of adult users, with only a few hundred confirmed cases globally.
- Primary strategy: Abstinence is the only effective therapeutic measure identified to date.
Historical context: From relief to paradox
To understand the severity of this syndrome, it is necessary to recall its positive counterpart. In the early 1980s, publications in prestigious journals such as the Journal of the American Medical Association documented that oral delta-9-tetrahydrocannabinol (THC) significantly reduced chemotherapy-induced nausea. This finding was crucial for patients whose quality of life depended on the control of these symptoms, occasionally preventing death from severe dehydration.
However, scientific progress in this field stalled for decades due to complex factors: the impossibility of patenting the whole plant, cultural prejudices, and methodological limitations in clinical trials. Systematic reviews, such as those conducted by the Cochrane Collaboration, confirmed the efficacy of cannabis for chemotherapy-induced vomiting but also noted that most available studies dated back to the late 20th century. Meanwhile, in real-world clinical practice and unsupervised recreational or medicinal use, new patterns of consumption emerged.
The global scientific literature began to record isolated cases around 2004. During the first few years, publications were scarce. However, starting in 2010, and especially in the last five years, the frequency of reports has increased dramatically. This increase should not necessarily be interpreted as a proportional rise in actual cases, but rather as greater diagnostic awareness among healthcare professionals.
Diagnostic criteria and the hot shower sign
Clinical diagnosis is based on strict criteria defined to avoid false positives. The central element is chronic cannabis use over many years; without this history, the syndrome cannot be diagnosed. Symptoms must present cyclically and severely, accompanied by localized abdominal pain (epigastric or umbilical) and significant weight loss.
The most peculiar, and perhaps the most revealing, characteristic of the clinical picture is the immediate relief of symptoms after taking hot baths or showers. In medical terminology, this sign is considered pathognomonic, meaning its presence confirms the differential diagnosis against other gastrointestinal pathologies with near certainty.
This paradoxical reaction—cannabis causes vomiting, yet heat relieves it—has led to various physiological hypotheses. It is known that both the brain’s vomiting center and the intestinal wall contain type CB1 cannabinoid receptors. In most people, these receptors inhibit the emetic reflex. However, in susceptible individuals, chronic consumption may have caused desensitization or functional alteration of these receptors in the digestive tract. The theory suggests that the sudden increase in body temperature (hot bath) acts on the enteric nerves, temporarily restoring homeostasis and stopping the nausea.
Prevalence: Between rarity and urgency
It is essential to maintain a realistic perspective on the magnitude of the problem. Despite sensationalist headlines, the syndrome is currently considered a rare entity. Estimates suggest it affects a minority percentage of regular users, with its incidence comparable to other serious but infrequent adverse effects of conventional drugs, such as metamizole-induced agranulocytosis.
In Europe, where cannabis use is relatively high in certain population segments, it is estimated that between 1% and 7% of adult users have manifested compatible symptoms. Although figures vary by region and consumption culture, the absolute number of confirmed cases remains low in global statistical terms.
Nevertheless, there is legitimate concern regarding the saturation of hospital emergency rooms. Some experts warn that this syndrome could be contributing to an increase in unscheduled visits. It is crucial to distinguish between responsible use and the intensive or unregulated patterns of use that predispose individuals to developing the condition.
Risk reduction and critical reading
Faced with this syndrome, the therapeutic strategy is clear and definitive: abstinence. Most standard pharmacological treatments for nausea (such as lorazepam or haloperidol) have proven ineffective in these patients. The only measure that guarantees the resolution of the condition is to stop cannabis use.
It is important to note that recovery is not always immediate or linear. Symptoms can persist for months or even years after stopping consumption, and returning to use, even occasionally, can cause a rapid return of emetic episodes in susceptible individuals. This underscores the importance of professional counseling before starting any cannabinoid treatment.
Furthermore, we must be cautious about simplistic causal interpretations. Is cannabis the only cause? It could be a synergistic effect with other factors: adulterants in unregulated products, varieties with specific chemical profiles, or individual genetic predispositions that alter the response to cannabinoids.
Comparison with other substances helps provide context. For example, intensive ketamine use has recently led to the diagnosis of ketamine-induced cystopathy, a serious renal injury not previously detected in decades of medical and recreational use. Similarly, cannabinoid hyperemesis could be a delayed effect of massive consumption that only manifests when the threshold of tolerance or physiological damage is exceeded.
Conclusion: Balancing benefit and risk
Cannabinoid hyperemesis syndrome invites us to reflect on the complexity of drug-receptor interactions. There is no “magic” substance; every compound has a safety profile that depends on the context of use, the dose, and individual physiology.
At Psiconáutica, we have always advocated for an approach based on scientific evidence and prudence. Cannabis remains a valid therapeutic tool for specific conditions such as chemotherapy-induced vomiting, but its use must be supervised and understood within its biological limits.
Freedom of choice does not imply immunity from physiological consequences. Recognizing the existence of this syndrome is a necessary step toward a safer and more responsible culture of consumption. The next time we consider using cannabinoids, let us remember that relief can have its counterpart, and that moderation is the best guarantee for preserving our long-term health.
Science advances, and with it, our understanding of how we interact with these powerful molecules. Staying informed, always consulting healthcare professionals, and prioritizing risk reduction are the fundamental pillars for navigating this pharmacological territory with awareness.
